Incyte Corporation $INCY Stock Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 5.2% during the third quarter, HoldingsChannel.com reports. The fund owned 403,382 shares of the biopharmaceutical company’s stock after selling 22,234 shares during the quarter. Russell Investments Group Ltd.’s holdings in Incyte were worth $49,044,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of INCY. BlackRock Inc. purchased a new stake in Incyte in the 2nd quarter worth $2,044,189,000. Wellington Management Group LLP boosted its holdings in shares of Incyte by 9.5% during the 2nd quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company’s stock valued at $405,321,000 after purchasing an additional 309,385 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Incyte by 10.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company’s stock valued at $185,873,000 after purchasing an additional 187,354 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Incyte during the second quarter valued at about $182,054,000. Finally, Pacer Advisors Inc. grew its position in shares of Incyte by 2.2% during the first quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company’s stock valued at $163,869,000 after purchasing an additional 37,790 shares in the last quarter. 96.97% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Thomas Tray sold 610 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total value of $72,565.60. Following the completion of the sale, the insider directly owned 21,126 shares in the company, valued at $2,513,148.96. This trade represents a 2.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo J. Cagnoni sold 10,801 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the completion of the sale, the insider owned 183,200 shares of the company’s stock, valued at approximately $23,002,592. This represents a 5.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 254,246 shares of company stock valued at $30,162,968. 16.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

INCY has been the topic of several research reports. Barclays lifted their target price on Incyte from $139.00 to $143.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Mizuho increased their price target on Incyte from $121.00 to $137.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Wall Street Zen cut Incyte from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Incyte in a research note on Tuesday, October 27th. Finally, UBS Group set a $152.00 price objective on Incyte in a research note on Friday, October 30th. Eleven research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $132.86.

View Our Latest Research Report on Incyte

Incyte Price Performance

Shares of INCY stock opened at $120.97 on Monday. Incyte Corporation has a 1 year low of $89.25 and a 1 year high of $132.60. The stock’s 50 day simple moving average is $119.18 and its two-hundred day simple moving average is $108.96. The company has a market cap of $24.66 billion, a PE ratio of 64.35, a price-to-earnings-growth ratio of 4.40 and a beta of 0.78.

Incyte (NASDAQ:INCY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.93) by $0.33. The business had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The company’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same period last year, the company earned $2.26 EPS. Equities research analysts expect that Incyte Corporation will post 2.24 EPS for the current year.

Incyte Company Profile

(Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

Recommended Stories

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.